Q32 Bio, Inc. (QTTB)
16.34
+0.37
(+2.32%)
USD |
NASDAQ |
Aug 24, 16:00
16.34
0.00 (0.00%)
After-Hours: 20:00
Q32 Bio Net Income (Quarterly) : -8.946M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.946M |
| March 31, 2026 | -7.609M |
| December 31, 2025 | 57.73M |
| September 30, 2025 | -7.389M |
| June 30, 2025 | -9.489M |
| March 31, 2025 | -11.03M |
| December 31, 2024 | -14.19M |
| September 30, 2024 | -17.60M |
| June 30, 2024 | -16.98M |
| March 31, 2024 | 1.029M |
| December 31, 2023 | -27.07M |
| September 30, 2023 | -14.03M |
| June 30, 2023 | -5.807M |
| March 31, 2023 | -6.838M |
| December 31, 2022 | -34.30M |
| September 30, 2022 | -33.73M |
| June 30, 2022 | -29.09M |
| March 31, 2022 | 92.10M |
| Date | Value |
|---|---|
| December 31, 2021 | -33.58M |
| September 30, 2021 | -30.61M |
| June 30, 2021 | -30.50M |
| March 31, 2021 | -1.073M |
| December 31, 2020 | -29.79M |
| September 30, 2020 | -28.23M |
| June 30, 2020 | -35.34M |
| March 31, 2020 | -35.33M |
| December 31, 2019 | -24.17M |
| September 30, 2019 | -29.63M |
| June 30, 2019 | -26.27M |
| March 31, 2019 | -23.85M |
| December 31, 2018 | -18.79M |
| September 30, 2018 | -14.15M |
| June 30, 2018 | -12.43M |
| March 31, 2018 | -10.22M |
| December 31, 2017 | -11.91M |
| September 30, 2017 | -6.528M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Rallybio Corp. | 43.66M |
| Beam Therapeutics, Inc. | -122.68M |
| C4 Therapeutics, Inc. | -23.64M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.946M |
| EPS Diluted (Quarterly) | -0.4398 |
| Enterprise Value | 278.10M |
| Earnings Yield | 18.37% |
| Operating Earnings Yield | 8.86% |
| Normalized Earnings Yield | 18.40 |